Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritis.
Sanjoy K PaulOlga MontvidaJennie H BestSara GaleAttila Pethö-SchrammKhaled SarsourPublished in: BMJ open (2021)
Treatment with IL-6i, with or without T-cell inhibitors, was associated with reduced risk for T2DM compared with TNFi or No bDMARDs; a less pronounced association was observed for the T-cell inhibitor abatacept.
Keyphrases
- rheumatoid arthritis
- type diabetes
- cardiovascular disease
- disease activity
- rheumatoid arthritis patients
- glycemic control
- interstitial lung disease
- ankylosing spondylitis
- stem cells
- mesenchymal stem cells
- metabolic syndrome
- insulin resistance
- adipose tissue
- skeletal muscle
- combination therapy
- cell therapy
- idiopathic pulmonary fibrosis
- breast cancer risk